Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity

World Journal of Urology

Volumn 29, Issue 1, 2011, Pages 51-57

  Padmanabhan, Priya ^a   Scarpero, Harriette M ^a   Milam, Douglas F ^a   Dmochowski, Roger R ^a   Penson, David F ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Botulinum toxin type A; Economics; Neurogenic bladder; Overactive detrusor

Indexed keywords

EID: 78751645634     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0618-3     Document Type: Article

References (33)

1. Herschorn S, Hewitt RJ (1998) Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology 52: 672.
2. Stohrer M, Schurch B, Kramer G et al (1999) Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 18: 401.
3. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510.
4. Karsenty G, Reitz A, Lindemann G et al (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68: 1193.
5. Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53: 1245.
6. Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49: 519.
7. Boy S, Seif C, Braun P (2008) Retrospective analysis of treatment outcomes and medical care of patients with neurogenic detrusor overactivity (NDO) receiving BOTOX therapy. Eur Urol Suppl 7: 212.
8. Del Popolo G, Li Marzi V, Lombardi G (2004) Efficacy, safety and dosage of English botulinum toxin-A in neurogenic detrusor overactivity. Eur Urol 3: A663.
9. Del Popolo G, Filocamo MT, Li Marzi V et al (2008) Neurogenic detrusor overactivity treated with English botulinum toxin a: 8-year experience of one single centre. Eur Urol 53: 1013.
10. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47: 653.
11. Reitz A, Denys P, Fermanian C et al (2007) Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52: 1729.
12. Chenet A, Perrouin-Verbe B, Le Normand L et al (2007) Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readapt Med Phys 50: 651.
13. Giannantoni A, Mearini E, Del Zingaro M et al (2009) Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 55: 705.
14. Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53: 275.
15. Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: 196.
16. Giannantoni A, Mearini E, Di Stasi SM et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56: 79.
17. Bagi P, Biering-Sorensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38: 495.
18. Schurch B, Stohrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692.
19. Schulte-Baukloh H, Schobert J, Stolze T et al (2006) Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 25: 110.
20. Kalsi V, Apostolidis A, Popat R et al (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49: 528.
21. Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63: 868.
22. Klaphajone J, Kitisomprayoonkul W, Sriplakit S (2005) Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 86: 2114.
23. Kennelly M, Kang J (2003) Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cord in J Rehabil 8: 46.
24. Pannek J, Gocking K, Bersch U (2009) Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 104: 1246.
25. Freedman ER, Singh G, Donnell SC et al (1994) Combined bladder neck suspension and augmentation cystoplasty for neuropathic incontinence in female patients. Br J Urol 73: 621.
26. Blyth B, Ewalt DH, Duckett JW et al (1992) Lithogenic properties of enterocystoplasty. J Urol 148: 575.
27. Rink RC (1999) Bladder augmentation. Options, outcomes, future. Urol Clin North Am 26: 111.
28. Greenwell TJ, Venn SN, Mundy AR (2001) Augmentation cystoplasty. BJU Int 88: 511.
29. Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO et al (2000) Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord 38: 490.
30. Gough DC (2001) Enterocystoplasty. BJU Int 88: 739.
31. Zachoval R, Pitha J, Medova E et al (2003) Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 70: 21.
32. Game X, Castel-Lacanal E, Bentaleb Y et al (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53: 613.
33. Chancellor MB (2009) Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol.